Loading...
NPI 1538154117 · Southaven, MS · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jorge Calzada is a retina specialist (ophthalmology) physician provider located in Southaven, Mississippi. This profile covers 33 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jorge Calzada |
| Address | 7900 Airways Blvd Bldg A1 |
| City | Southaven |
| State | MS |
| ZIP | 38671 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | September 20, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.3M |
| Medicaid | $10 |
This provider is effectively a Medicare-centric retinal specialist: lifetime Medicare revenue is $2.3M while lifetime Medicaid revenue is $7, indicating the practice’s payer mix is overwhelmingly Medicare-driven and functionally single-payer in scale. The NPI was enumerated on 2005-09-20 (~21 years ago), consistent with an established independent clinical presence in Southaven, MS.
Revenue concentration is high: the precomputed top-3 Medicare codes account for 65.7% of total Medicare revenue, signaling dependence on a small set of high-value intravitreal drug administrations and related services. The largest single Medicare line is J2778 with $583.1K (25.8% of Medicare revenue), followed by J2777 with $567.2K (25.1%), and J0178 with $335.4K (14.8%).
The CPT/HCPCS mix indicates an office-based retina practice driven by intravitreal pharmacotherapy and diagnostics: high-volume retinal drug codes J2778, J2777, J0178, and J2781 dominate revenue and correspond to ranibizumab, faricimab, aflibercept, and pegcetacoplan injections, while imaging codes 92134 and 92250 and evaluation codes 92014/92004 support a high-throughput outpatient diagnostic workflow. Surgical retinal procedures such as 67042, 67036, and 67108 appear at lower revenue levels, consistent with a practice that performs some surgical cases but derives most revenue from injections and office diagnostics.
Competitive standing on key drug codes is mixed: J2778 ranks #96 of 1208 providers nationally (92th percentile) and J2781 ranks #33 of 490 (93th percentile), indicating above-typical national activity for those agents, while J0178 ranks #1958 of 3204 (39th percentile) and J2777 ranks #548 of 2039 (73th percentile), reflecting more modest-to-typical participation in aflibercept and faricimab relative to national peers. Imaging and evaluation volumes are unusually high: 92014 ranks #804 of 35415 (98th percentile) and 92134 ranks #1037 of 26868 (96th percentile), which suggests stronger-than-typical utilization of comprehensive established exams and retinal OCT imaging.
Operational implications: the practice likely focuses on frequent follow-up visits and recurring intravitreal therapy administration workflows given J2778 (3.3K claims) and J2777 (19.6K claims) claim volumes, supported by high counts for 92134 (2K claims) and routine established-patient visits under 92014 (1.4K claims). This mix implies needs for infusion/injection nursing, drug inventory and billing processes tuned to high-volume ophthalmic biologics, and capacity for same-day diagnostics.
Service-level outliers and notable policy flags for utilization: several retinal imaging and exam codes are labeled “notably above typical” (92014 and 92134), underscoring significantly higher-than-typical billing for those outpatient services compared with national peers. Conversely, a few drug or procedure codes show typical or below-typical standing (for example, J3490 ranks #2134 of 2838, 23th percentile, and J0178 is 39th percentile), indicating the practice’s strength is concentrated in a subset of agents and services rather than across all retinal therapeutics.
Surgical footprint is present but limited: vitrectomy and complex retinal repair codes such as 67042 ($43K, 54 claims, 92th percentile) and 67028 ($140.1K, 1.7K claims, 86th percentile) appear in the portfolio but contribute a minority of Medicare revenue. These entries suggest the provider maintains surgical capability and handles some retina surgeries, but the bulk of revenue and patient throughput is driven by in-office injections and imaging.
Ancillary billing patterns: relatively large per-claim payments for a small number of unclassified drug entries (J3490: $56.6K revenue at $1714 avg paid/claim) and the presence of high-average-payment surgical codes (e.g., 67042 at $796 avg) indicate occasional high-dollar items in the ledger, but these do not materially alter the overall Medicare revenue concentration dominated by the top three codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
33 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2778 | Injection, ranibizumab, 0.1 mg | 3,280 | $180 | $583.1K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 19,560 | $30 | $567.2K |
| J0178 | Injection, aflibercept, 1 mg | 480 | $690 | $335.4K |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 1,880 | $120 | $225K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,710 | $80 | $140.1K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,360 | $80 | $101.8K |
| J3490 | Unclassified drugs | 30 | $1,710 | $56.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,990 | $30 | $53.8K |
| 67042 | In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina… | 50 | $800 | $43K |
| J9035 | Injection, bevacizumab, 10 mg | 550 | $50 | $29.8K |
Showing 1–10 of 33
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 33 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
33 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J2778 | 2 | 10 | 1,300 | $180 | $1.3M |
| J0178 | 13 | 20 | 670 | $680 | $990.1K |
| J2777 | 2 | 10 | 8,460 | $30 | $325.2K |
| J2781 | 1 | 10 | 950 | $120 | $141.8K |
| 67028 | 6 | 30 | 600 | $80 | $107K |
| 67042 | 1 | 10 | 30 | $1,000 | $27.9K |
| 67036 | 7 | 10 | 20 | $890 | $25.7K |
| 92014 | 9 | 350 | 170 | $70 | $23K |
| 99214 | 3,596 | 4,110 | 170 | $70 | $21.9K |
| 67113 | 5 | 10 | 20 | $1,040 | $19.8K |
Showing 1–10 of 33
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 30 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 30 | 40 | 70 | $10 | $19.3K |
Other providers in the same ZIP code as Jorge Calzada, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.